Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
NCT ID: NCT03874117
Last Updated: 2025-09-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
58 participants
INTERVENTIONAL
2018-07-01
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
NCT02225782
Hemodialysis-based Interventions to Preserve Cognitive Function
NCT02697942
Coupling Between Clotting Characteristics in Chronic Hemodialysis Patients and the Hemodialyzer Patency
NCT05440201
Optimisation of Anticoagulation in Patients on Nocturnal Hemodialysis
NCT05204810
Impact of Residual Renal Function on Complications in Chronic Hemodialysis Patients
NCT03854513
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* been on hemodialysis for at least 3 months.
* adherence to regular dialysis treatments.
Exclusion Criteria
* planned revision of hemodialysis vascular access.
* hospitalized within the past 2 months.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Palo Alto Veterans Institute for Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tammy Sirich
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tammy Sirich, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford/VA Palo Alto Health Care System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Palo Alto Health Care System
Palo Alto, California, United States
Santa Clara Valley Medical Center
San Jose, California, United States
Satellite HealthCare
San Jose, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lee S, Pham NM, Montez-Rath ME, Bolanos CG, Bonde SS, Meyer TW, Sirich TL. Twice Weekly versus Thrice Weekly Hemodialysis-A Pilot Cross-Over Equivalence Trial. Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1159-1168. doi: 10.2215/CJN.0000000000000507. Epub 2024 Jun 26.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIT0003AGG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.